WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562702
CAS#: 1430208-73-3
Description: 1A-116 is a specific Rac1 inhibitor.
Hodoodo Cat#: H562702
Name: 1A-116
CAS#: 1430208-73-3
Chemical Formula: C16H16F3N3
Exact Mass: 307.13
Molecular Weight: 307.320
Elemental Analysis: C, 62.53; H, 5.25; F, 18.55; N, 13.67
Synonym: 1A-116; 1A 116; 1A116;
IUPAC/Chemical Name: N-(3,5-Dimethylphenyl)-N'-[2-(trifluoromethyl)phenyl]-guanidine
InChi Key: DVIJFJSZZNOTLP-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H16F3N3/c1-10-7-11(2)9-12(8-10)21-15(20)22-14-6-4-3-5-13(14)16(17,18)19/h3-9H,1-2H3,(H3,20,21,22)
SMILES Code: N=C(NC1=CC=CC=C1C(F)(F)F)NC2=CC(C)=CC(C)=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | 1A-116 is a Rac1 inhibitor. |
| In vitro activity: | To evaluate the effect of 1A-116 on cell proliferation in leukemic cells, this study measured cell viability by the MTS metabolic assay. 1A-116 inhibited cell proliferation in a concentration-dependent manner, showing enhanced efficacy in Jurkat cells reaching a 100% inhibition in cell proliferation. Moreover, in the more undifferentiated cellular models of myeloid leukemia (HL-60 and KG1A), 1A-116 showed a left shift in the concentration response curves indicating an increased potency in its antiproliferative activity (Figure 9A). Reference: Oncotarget. 2017 Nov 17; 8(58): 98509–98523. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716746/ |
| In vivo activity: | TBD |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 65.4 | 212.69 | |
| Ethanol | 30.7 | 99.99 |
The following data is based on the product molecular weight 307.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Cabrera M, Echeverria E, Lenicov FR, Cardama G, Gonzalez N, Davio C, Fernández N, Menna PL. Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget. 2017 Oct 4;8(58):98509-98523. doi: 10.18632/oncotarget.21533. PMID: 29228706; PMCID: PMC5716746. 2. Gonzalez N, Cardama GA, Comin MJ, Segatori VI, Pifano M, Alonso DF, Gomez DE, Menna PL. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. Cell Signal. 2017 Jan;30:154-161. doi: 10.1016/j.cellsig.2016.12.002. Epub 2016 Dec 7. PMID: 27939839. |
| In vitro protocol: | 1. Cabrera M, Echeverria E, Lenicov FR, Cardama G, Gonzalez N, Davio C, Fernández N, Menna PL. Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget. 2017 Oct 4;8(58):98509-98523. doi: 10.18632/oncotarget.21533. PMID: 29228706; PMCID: PMC5716746. 2. Gonzalez N, Cardama GA, Comin MJ, Segatori VI, Pifano M, Alonso DF, Gomez DE, Menna PL. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. Cell Signal. 2017 Jan;30:154-161. doi: 10.1016/j.cellsig.2016.12.002. Epub 2016 Dec 7. PMID: 27939839. |
| In vivo protocol: | TBD |
1: Cabrera M, Echeverria E, Lenicov FR, Cardama G, Gonzalez N, Davio C, Fernández N, Menna PL. Pharmacological Rac1 inhibitors with selective apoptotic activity in human acute leukemic cell lines. Oncotarget. 2017 Oct 4;8(58):98509-98523. doi: 10.18632/oncotarget.21533. eCollection 2017 Nov 17. PubMed PMID: 29228706; PubMed Central PMCID: PMC5716746.
2: Rudenko IN, Kaganovich A, Langston RG, Beilina A, Ndukwe K, Kumaran R, Dillman AA, Chia R, Cookson MR. The G2385R risk factor for Parkinson's disease enhances CHIP-dependent intracellular degradation of LRRK2. Biochem J. 2017 Apr 24;474(9):1547-1558. doi: 10.1042/BCJ20160909. PubMed PMID: 28320779.
3: Gonzalez N, Cardama GA, Comin MJ, Segatori VI, Pifano M, Alonso DF, Gomez DE, Menna PL. Pharmacological inhibition of Rac1-PAK1 axis restores tamoxifen sensitivity in human resistant breast cancer cells. Cell Signal. 2017 Jan;30:154-161. doi: 10.1016/j.cellsig.2016.12.002. Epub 2016 Dec 7. PubMed PMID: 27939839.
4: Cardama GA, Gonzalez N, Ciarlantini M, Gandolfi Donadío L, Comin MJ, Alonso DF, Menna PL, Gomez DE. Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. Onco Targets Ther. 2014 Oct 30;7:2021-33. doi: 10.2147/OTT.S67998. eCollection 2014. PubMed PMID: 25378937; PubMed Central PMCID: PMC4218912.
5: Cardama GA, Comin MJ, Hornos L, Gonzalez N, Defelipe L, Turjanski AG, Alonso DF, Gomez DE, Menna PL. Preclinical development of novel Rac1-GEF signaling inhibitors using a rational design approach in highly aggressive breast cancer cell lines. Anticancer Agents Med Chem. 2014;14(6):840-51. PubMed PMID: 24066799; PubMed Central PMCID: PMC4104455.
6: Rudenko IN, Chia R, Cookson MR. Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease? BMC Med. 2012 Feb 23;10:20. doi: 10.1186/1741-7015-10-20. Review. PubMed PMID: 22361010; PubMed Central PMCID: PMC3308210.
